{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T17:13:15Z","timestamp":1791133995357,"version":"4.1.0"},"reference-count":83,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2013,1,9]],"date-time":"2013-01-09T00:00:00Z","timestamp":1357689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0052562","type":"journal-article","created":{"date-parts":[[2013,1,10]],"date-time":"2013-01-10T00:15:05Z","timestamp":1357776905000},"page":"e52562","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":100,"title":["Clinical Use of HIV Integrase Inhibitors: A Systematic Review and Meta-Analysis"],"prefix":"10.1371","volume":"8","author":[{"given":"Peter","family":"Messiaen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie M. J.","family":"Wensing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Fun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Nijhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nele","family":"Brusselaers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linos","family":"Vandekerckhove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,1,9]]},"reference":[{"key":"ref1","unstructured":"Joint United Nations Programme on HIV\/AIDS. Global report: UNAIDS report on the global AIDS epidemic 2010. Accessible at <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.unaids.org\/globalreport\/documents\/20101123_GlobalReport_full_en.pdf\" xlink:type=\"simple\">http:\/\/www.unaids.org\/globalreport\/documents\/20101123_GlobalReport_full_en.pdf<\/ext-link>. <underline>Accessed 16\/10\/2012<\/underline> 2012\/10\/16. Geneva."},{"key":"ref2","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMoa0708975","article-title":"Raltegravir with optimized background therapy for resistant HIV-1 infection","volume":"359","author":"RT Steigbigel","year":"2008","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1086\/630210","article-title":"High rate of virologic suppression with raltegravir plus etravirine and darunavir\/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial","volume":"49","author":"Y Yazdanpanah","year":"2009","journal-title":"Clin Infect Dis"},{"key":"ref4","unstructured":"Department of Health and Human Services. DHHS Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents - October 14, 2011. Accessible at <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.aidsinfo.nih.gov\/Guidelines\/GuidelineDetail.aspx?GuidelineID=7\" xlink:type=\"simple\">http:\/\/www.aidsinfo.nih.gov\/Guidelines\/GuidelineDetail.aspx?GuidelineID=7<\/ext-link>. Accessed 2012\/10\/16."},{"key":"ref5","unstructured":"European AIDS Clinical Society. EACS European Guidelines for treatment of HIV infected adults in Europe. Accessible at <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.europeanaidsclinicalsociety.org\/index.php?option=com_content&view=article&id=59&Itemid=41\" xlink:type=\"simple\">http:\/\/www.europeanaidsclinicalsociety.org\/index.php?option=com_content&amp;view=article&amp;id=59&amp;Itemid=41<\/ext-link>. Accessed 2012\/10\/16."},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.jclinepi.2010.11.022","article-title":"Finding evidence for comparing medical interventions: AHRQ and the Effective Health Care Program","volume":"64","author":"R Relevo","year":"2011","journal-title":"Journal of clinical epidemiology"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"D Moher","year":"2009","journal-title":"PLoS medicine"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jclinepi.2009.03.009","article-title":"AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions\u2013agency for healthcare research and quality and the effective health-care program","volume":"63","author":"DK Owens","year":"2010","journal-title":"Journal of clinical epidemiology"},{"key":"ref9","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"N Mantel","year":"1959","journal-title":"Journal of the National Cancer Institute"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1097\/SMJ.0b013e31817a7ee4","article-title":"Odds ratios and risk ratios: what&apos;s the difference and why does it matter?","volume":"101","author":"AJ Viera","year":"2008","journal-title":"Southern medical journal"},{"key":"ref11","unstructured":"US Department of Health and Human Services Food and Drug Administration CfDEaR (2002) Guidance for industry: antiretroviral drugs using plasma HIV RNA measurements. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm070968.pdf\" xlink:type=\"simple\">http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm070968.pdf<\/ext-link> Accessed 2012\/08\/23."},{"key":"ref12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/1740774509356117","article-title":"Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field","volume":"7","author":"L Wittkop","year":"2010","journal-title":"Clinical trials (London, England)"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1310\/hct1303-119","article-title":"A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naive HIV-infected patients: SPARTAN study results","volume":"13","author":"MJ Kozal","year":"2012","journal-title":"HIV clinical trials"},{"key":"ref14","unstructured":"Walmsley S, Antela A, Clumeck N, Duiculescu D, Eberhard A, <etal>et al<\/etal>.. (2012) Dolutegravir (DTG; S\/GSK1349572) + Abacavir\/Lamivudine Once Daily Statistically Superior to Tenofovir\/Emtricitabine\/Efavirenz: 48-Week Results - SINGLE (ING114467). Abstract H-556b. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco."},{"key":"ref15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAI.0b013e3181da1287","article-title":"Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses","volume":"55","author":"JL Lennox","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S0140-6736(09)60918-1","article-title":"Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial","volume":"374","author":"JL Lennox","year":"2009","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Rockstroh J, Lazarrin A, Zhao J, Rodgers A, DiNubile M, <etal>et al<\/etal>.. (2011) Long-term Efficacy of Raltegravir (RAL) or Efavirenz (EFV) Combined with Tenofovir (TDF) and Emtricitabine (FTC) in Treatment-naive HIV-1 Patients: Wk-192 Subgroup Analyses from STARTMRK Study. Abstract-No: PE7.9\/17. 13th European AIDS Clinical Society Conference. Belgrade.","DOI":"10.1310\/hct1304-228"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/cid\/cir510","article-title":"Long-term treatment with raltegravir or efavirenz combined with tenofovir\/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK","volume":"53","author":"JK Rockstroh","year":"2011","journal-title":"Clin Infect Dis"},{"key":"ref19","unstructured":"Rockstroh J, DeJesus E, Saag M, Yazdanpanah Y, Lennox J, <etal>et al<\/etal>.. (2012) Long-term safety and efficacy of raltegravir (RAL)-based versus efavirenz (EFV)-based combination therapy in treatment-na\u00efve HIV-1-infected patients: final 5-year double-blind results from STARTMRK. Abstract LBPE19. XIX International AIDS Conference. Washington DC."},{"key":"ref20","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/QAI.0b013e3181b064b0","article-title":"Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection","volume":"52","author":"M Markowitz","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/QAI.0b013e318157131c","article-title":"Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study","volume":"46","author":"M Markowitz","year":"2007","journal-title":"Journal of acquired immune deficiency syndromes (1999)"},{"key":"ref22","unstructured":"Gotuzzo E, Nguyen BY, Markowitz M, Mendo F, Ratanasuwan W, <etal>et al<\/etal>.. (2011) Sustained efficacy and tolerability of raltegravir after 240 weeks of combination ART in treatment-naive HIV-1-infected patients; final analysis of protocol 004. Abstract no. EPDB0102 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome."},{"key":"ref23","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S1473-3099(11)70196-7","article-title":"Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial","volume":"11","author":"JJ Eron Jr","year":"2011","journal-title":"The Lancet infectious diseases"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1310\/hct1204-228","article-title":"96-week results of a pilot study of abacavir\/lamivudine and raltegravir in antiretroviral-naive HIV-1-infected patients: the SHIELD trial","volume":"12","author":"B Young","year":"2011","journal-title":"HIV Clin Trials"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/S0140-6736(12)60917-9","article-title":"Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks","volume":"379","author":"PE Sax","year":"2012","journal-title":"Lancet"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"F7","DOI":"10.1097\/QAD.0b013e328345766f","article-title":"Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate versus efavirenz\/emtricitabine\/tenofovir disoproxil fumarate for the initial treatment of HIV infection","volume":"25","author":"C Cohen","year":"2011","journal-title":"Aids"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Rockstroh J, Felizarta F, Maggiolo F, Pulido F, Stellbrink H, <etal>et al<\/etal>.. (2010) Once-daily S\/GSK1349572 combination therapy in antiretroviral-na\u00efve adults: Rapid and potent 24-week antiviral responses in SPRING-1 (ING112276). Abstract O50. Tenth International Congress on Drug Therapy in HIV Infection. Glasgow, United Kingdom.","DOI":"10.1186\/1758-2652-13-S4-O50"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S1473-3099(11)70290-0","article-title":"Once daily dolutegravir (S\/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial","volume":"12","author":"J van Lunzen","year":"2011","journal-title":"The Lancet infectious diseases"},{"key":"ref29","unstructured":"van Lunzen J, Maggiolo F, Phung B, Tsybakova O, Young B, <etal>et al<\/etal>.. (2011) Rapid, robust and sustained antiviral response with once-daily (QD) dolutegravir (DTG, S\/GSK1349572), a next generation integrase inhibitor (INI) in combination therapy in antiretroviral-na\u00efve adults: 48 week results from SPRING-1 (ING112276). Abstract no. TUAB0102 6th IAS Conference on HIV pathogenesis, treatment and prevention. Rome."},{"key":"ref30","unstructured":"Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, <etal>et al<\/etal>.. (2012) Once-daily dolutegravir (DTG; S\/GSK1349572) is non-inferior to raltegravir (RAL) in antiretroviral-naive adults: 48 week results from SPRING-2 (ING113086). Abstract THLBB04. XIX International AIDS Conference. Wasgington DC."},{"key":"ref31","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1016\/S0140-6736(12)60918-0","article-title":"Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"379","author":"E DeJesus","year":"2012","journal-title":"Lancet"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1310\/hct1205-255","article-title":"Examination of noninferiority, safety, and tolerability of lopinavir\/ritonavir and raltegravir compared with lopinavir\/ritonavir and tenofovir\/emtricitabine in antiretroviral-naive subjects: the progress study, 48-week results","volume":"12","author":"J Reynes","year":"2011","journal-title":"HIV clinical trials"},{"key":"ref33","unstructured":"Bedimo R, Drechsler H, Turner D, Moore T, Ghormley J, <etal>et al<\/etal>.. (2011) RADAR study: Raltegravir combined with boosted Darunavir has similar safety and antiviral efficacy as tenofovir\/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Abstract no. MOPE214. 6th IAS Conference on HIV pathogenesis, treatment and prevention. Rome."},{"key":"ref34","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1097\/QAD.0b013e32834bbaa9","article-title":"Efficacy of a nucleoside-sparing regimen of darunavir\/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)","volume":"25","author":"B Taiwo","year":"2011","journal-title":"Aids"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1086\/650002","article-title":"Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials","volume":"50","author":"RT Steigbigel","year":"2010","journal-title":"Clin Infect Dis"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/QAI.0b013e3181c9c967","article-title":"Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study","volume":"53","author":"JM Gatell","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0140-6736(07)60597-2","article-title":"Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial","volume":"369","author":"B Grinsztejn","year":"2007","journal-title":"Lancet"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1086\/650698","article-title":"Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial","volume":"201","author":"AR Zolopa","year":"2010","journal-title":"J Infect Dis"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Canestri A, Blanc C, Wirden M, Peytavin G, Ktorza N, <etal>et al<\/etal>.. (2008) Efficacy and safety of an antiretroviral regimen containing etravirine plus raltegravir in HIV-1 treatment-experienced patients failing darunavir. Abstract P38. Nineth International Congress on Drug Therapy in HIV Infection. Glasgow.","DOI":"10.1186\/1758-2652-11-S1-P38"},{"key":"ref40","unstructured":"Fagard C, Descamps D, Colin C, Taburet AM, Molina JM, <etal>et al<\/etal>.. (2011) Long Term Follow-up of Patients Receiving Raltegravir, Etravirine and Darunavir\/ritonavir in the ANRS 139 TRIO Trial. Abstract #549. 18th Conference on Retroviruses and Opportunistic Infections. Boston."},{"key":"ref41","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1097\/QAD.0b013e3283372d76","article-title":"Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience","volume":"24","author":"S Nozza","year":"2010","journal-title":"AIDS (London, England)"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3109\/00365541003621502","article-title":"Raltegravir as functional monotherapy leads to virological failure and drug resistance in highly treatment-experienced HIV-infected patients","volume":"42","author":"F Caby","year":"2010","journal-title":"Scandinavian journal of infectious diseases"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1473-3099(11)70249-3","article-title":"Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study","volume":"12","author":"JM Molina","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"ref44","unstructured":"Margot NA, Rhee M, Szwarcberg J, Miller MD, GS-US-183-0145 Study Team (2012) Low rates of integrase resistance for elvitegravir and raltegravir through week 96 in the phase 3 clinical study GS-US-183-0145. Abstract TUPE050. XIX International AIDS Conference. Washington DC."},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Eron JJ, Livrozet JM, Morlat M, Lazzarin A, Katlama C, <etal>et al<\/etal>.. (2010) Activity of the integrase inhibitor S\/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: Week 24 results of the VIKING study (ING112961). Abstract O51. Tenth International Congress on Drug Therapy in HIV Infection. Glasgow, United Kingdom.","DOI":"10.1186\/1758-2652-13-S4-O51"},{"key":"ref46","unstructured":"Soriano V, Cox J, Eron JJ, Kumar P, Katlama C, <etal>et al<\/etal>.. (2011) Dolutegravir (DTG, S\/GSK1349572) Treatment of Subjects with Raltegravir (RAL) Resistance: Viral Suppression at Week 24 in the VIKING Study. Abstract-No: PS1\/2 13th European AIDS Clinical Society Conference. Belgrade."},{"key":"ref47","unstructured":"Eron JJ, Kumar P, Lazzarin A, Richmond G, Soriano V, <etal>et al<\/etal>.. (2011) Dolutegravir in Subjects with HIV Exhibiting RAL Resistance: Functional Monotherapy Results of VIKING Study Cohort II. Abstract no 151LB. 18th Conference on Retroviruses and Opportunistic Infections Boston."},{"key":"ref48","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S0140-6736(09)62041-9","article-title":"Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials","volume":"375","author":"JJ Eron","year":"2010","journal-title":"Lancet"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1097\/QAD.0b013e32833a608a","article-title":"Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study","volume":"24","author":"E Martinez","year":"2011","journal-title":"AIDS (London, England)"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1093\/jac\/dkr269","article-title":"Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial","volume":"66","author":"S Gallien","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1097\/QAD.0b013e328302f3b5","article-title":"Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen","volume":"22","author":"M Harris","year":"2008","journal-title":"Aids"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1310\/hct1006-432","article-title":"Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression","volume":"10","author":"JR Santos","year":"2009","journal-title":"HIV Clin Trials"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/QAI.0b013e3181aa1398","article-title":"Switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and safety at 24 weeks in a Montreal cohort","volume":"51","author":"A Talbot","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/QAI.0b013e3181ae35de","article-title":"Virologic outcomes of changing enfuvirtide to raltegravir in HIV-1 patients well controlled on an enfuvirtide based regimen: 24-week results of the CHEER study","volume":"51","author":"W Towner","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1310\/hct1104-197","article-title":"Simplification from protease inhibitors to once- or twice-daily raltegravir: the ODIS trial","volume":"11","author":"E Vispo","year":"2010","journal-title":"HIV clinical trials"},{"key":"ref56","unstructured":"Di Giambenedetto S, Fabbiani M, Colafigli M, Bracciale L, d&apos;Ettore G, <etal>et al<\/etal>.. (2011) Safety and efficacy of treatment switch to raltegravir plus tenofovir\/emtricitabine or abacavir\/lamivudine in patients on PI, NNRTI or NRTI-based therapy with optimal virologic control: 24 weeks results from a randomized pilot study. Abstract no. CDB365 6th IAS Conference on HIV pathogenesis, treatment and prevention. Rome."},{"key":"ref57","unstructured":"Reliquet V, Chirouze C, Muret P, Peytavin G, Ferr\u00e9 V, <etal>et al<\/etal>.. (2011) Raltegravir (RAL) and nevirapine (NVP) dual therapy maintains virologic suppression in HIV-infected HAART-treated patients: 48-week results of a pilot study. Abstract no. CDB363 6th IAS Conference on HIV pathogenesis, treatment and prevention. Rome."},{"key":"ref58","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/nm.2111","article-title":"HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects","volume":"16","author":"MJ Buzon","year":"2010","journal-title":"Nature medicine"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1093\/infdis\/jir559","article-title":"Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial","volume":"204","author":"H Byakwaga","year":"2011","journal-title":"The Journal of infectious diseases"},{"key":"ref60","unstructured":"Cesar C, Patterson P, V\u00e1zquez ML, Zapiola I, Saracco M, <etal>et al<\/etal>.. (2011) Raltegravir intensification in HIV-infected patients with immune discordant response to HAART. Abstract no. MOPE166. 6th IAS Conference on HIV pathogenesis, treatment and prevention. Rome."},{"key":"ref61","article-title":"No Effect of Raltegravir Intensification on Viral Replication Markers in the Blood of HIV-1-infected Patients Receiving Antiretroviral Therapy","author":"RT Gandhi","year":"2011","journal-title":"Journal of acquired immune deficiency syndromes (1999)"},{"key":"ref62","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000321","article-title":"The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial","volume":"7","author":"RT Gandhi","year":"2010","journal-title":"PLoS medicine"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/QAI.0b013e3181c42ea4","article-title":"Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy","volume":"54","author":"H Hatano","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref64","unstructured":"Lichtenstein K, Harbeck R, Nagabhushanam V, Hiserote M, Efaw B, <etal>et al<\/etal>.. (2010) A pilot study to assess the immunological response when raltegravir is added to a virologically suppressed HAART regimen. Abstract no. CDB0165. XVIII International AIDS Conference. Vienna."},{"key":"ref65","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1086\/650749","article-title":"Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy","volume":"50","author":"D McMahon","year":"2010","journal-title":"Clinical infectious diseases"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1093\/infdis\/jir667","article-title":"Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy","volume":"204","author":"V Dahl","year":"2012","journal-title":"The Journal of infectious diseases"},{"key":"ref67","unstructured":"Allavena C, Mounoury O, Rodallec A, Dailly E, Jovelin T, <etal>et al<\/etal>.. (2009) Raltegravir plus a boosted protease inhibitor: experience of a novel dual combination in HIV-infected antiretroviral-experienced patients. Abstract-No: PE7.9\/17. 12th European AIDS Clinical Society Conference Koln."},{"key":"ref68","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.3851\/IMP1647","article-title":"Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients","volume":"15","author":"DV Cordery","year":"2010","journal-title":"Antivir Ther"},{"key":"ref69","unstructured":"Ripamonti D, Maggiolo F, Bombana E, Gregis G, Quinzan G, <etal>et al<\/etal>.. (2009) Efficacy, safety and tolerability of dual therapy with raltegravir and atazanavir in antiretroviral experienced patients. Abstract no. MOPEB067. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa."},{"key":"ref70","unstructured":"Tsukada K, Nishijima T, Gatanaga H, Kanaya F, Kikuchi Y, <etal>et al<\/etal>.. (2011) Efficacy of NRTI-sparing regimen of raltegravir plus boosted darunavir in NRTI intolerant patients. Abstract no. CDB353 6th IAS Conference on HIV pathogenesis, treatment and prevention. Rome."},{"key":"ref71","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/1545109711422124","article-title":"Adherence and Preexisting Major Protease Inhibitor Resistance Mutations are Associated with Virologic Failure of a Dual-Class Antiretroviral Regimen with Inhibitors of HIV-1 Viral Protease and Integrase","volume":"11","author":"EM Gardner","year":"2012","journal-title":"Journal of the International Association of Physicians in AIDS Care Chicago, Ill"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.2010.1004","article-title":"Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel","volume":"304","author":"MA Thompson","year":"2010","journal-title":"JAMA"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1128\/AAC.01733-09","article-title":"Cross-resistance profile determination of two second-generation HIV-1 integrase inhibitors using a panel of recombinant viruses derived from raltegravir-treated clinical isolates","volume":"55","author":"L Van Wesenbeeck","year":"2011","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/jac\/dkp423","article-title":"Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection","volume":"65","author":"C Garrido","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"10366","DOI":"10.1128\/JVI.00470-08","article-title":"Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors","volume":"82","author":"O Goethals","year":"2008","journal-title":"J Virol"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/infdis\/jir636","article-title":"Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S\/GSK1349572) using clonal viral variants selected in patients failing raltegravir","volume":"204","author":"F Canducci","year":"2011","journal-title":"The Journal of infectious diseases"},{"key":"ref77","unstructured":"Hightower K, Wang R, Seki T, Kobayashi M, Underwood M (2011) Slow dissociation of Dolutegravir (S\/GSK1349572) contributes to an improved resistance profile with integrase inhibitor-resistant mutants. Abstract O_02. 9th European Workshop on HIV &amp; Hepatitis Treatment Strategies &amp; Antiviral Drug Resistance. Paphos, Cyprus."},{"key":"ref78","unstructured":"Clotet B, Katlama C, Soriano V, Lazzarin A, Richmond GJ, <etal>et al<\/etal>.. (2011) HIV Integrase resistance and phenotypic susceptibility to Dolutegravir (DTG, S\/GSK1349572) for subjects with virological failure on Raltegravir (RAL) Abstract O_03. 9th European Workshop on HIV &amp; Hepatitis Treatment Strategies and Antiviral Drug Resistance. Paphos, Cyprus."},{"issue":"Suppl 4","key":"ref79","doi-asserted-by":"crossref","first-page":"P58","DOI":"10.1186\/1758-2652-13-S4-P58","article-title":"A comparison of the FDA TLOVR and FDA Snapshot algorithms based on studies evaluating once-daily vs twice daily lopinavir\/ritonavir (LPV\/r) regimens","volume":"2010","author":"R Qaqish","year":"2010","journal-title":"Journal of the International AIDS Society"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/009286151104500309","article-title":"A meta-analysis to assess the FDA DAVP&apos;s TLOVR algorithm in HIV submissions","volume":"45","author":"F Smith","year":"2011","journal-title":"Drug Inf J"},{"key":"ref81","unstructured":"Zhang W, Pannucci M, Guo J, Hall D (2011) Comparison of TLOVR Algorithm Versus Snapshot Approach for HIV Studies. Abstract - #301734. 2011 Joint Statistical Meetings. Miami."},{"key":"ref82","unstructured":"Perinatal HIV Guidelines Working Group. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States\u2014September 14, 2011. Accessible at <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.aidsinfo.nih.gov\/ContentFiles\/PerinatalGL.pdf\" xlink:type=\"simple\">http:\/\/www.aidsinfo.nih.gov\/ContentFiles\/PerinatalGL.pdf<\/ext-link>. Accessed 2012\/10\/16."},{"key":"ref83","unstructured":"Fallon JP, Kurusa G, Correll TA, Qaqish RB, Woodward WC, <etal>et al<\/etal>.. (2010) Safety and efficacy of lopinavir\/ritonavir (LPV\/r) in combination with raltegravir (RAL) in HIV-infected subjects: 24 week interim analysis. Abstract no. THPE0070. XVIII International AIDS Conference. Vienna."}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0052562","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T15:16:59Z","timestamp":1687965419000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0052562"}},"subtitle":[],"editor":[{"given":"Luis","family":"Men\u00e9ndez-Arias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,1,9]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2013,1,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0052562","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,9]]}}}